In late December 2025, Sanofi secured European Commission approval for Wayrilz (rilzabrutinib), the first BTK inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback